These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26279303)

  • 1. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.
    Meng Z; Jia LF; Gan YH
    Oncogene; 2016 May; 35(18):2333-44. PubMed ID: 26279303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN.
    Zhang G; Gan YH
    Oncol Rep; 2017 Nov; 38(5):2657-2666. PubMed ID: 29048666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC6-mediated deacetylation of FLOT2 maintains stability and tumorigenic function of FLOT2 in nasopharyngeal carcinoma.
    Luo C; Wen B; Liu J; Yang W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 May; 49(5):687-697. PubMed ID: 39174882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKT activation controls cell survival in response to HDAC6 inhibition.
    Kaliszczak M; Trousil S; Ali T; Aboagye EO
    Cell Death Dis; 2016 Jun; 7(6):e2286. PubMed ID: 27362804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.
    Kaliszczak M; Trousil S; Åberg O; Perumal M; Nguyen QD; Aboagye EO
    Br J Cancer; 2013 Feb; 108(2):342-50. PubMed ID: 23322205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells.
    Pai JT; Hsu CY; Hua KT; Yu SY; Huang CY; Chen CN; Liao CH; Weng MS
    Molecules; 2015 May; 20(5):8000-19. PubMed ID: 25946558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of mutant hERG stability by inhibition of HDAC6.
    Li P; Kurata Y; Endang M; Ninomiya H; Higaki K; Taufiq F; Morikawa K; Shirayoshi Y; Horie M; Hisatome I
    J Mol Cell Cardiol; 2018 Feb; 115():158-169. PubMed ID: 29355491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
    Namdar M; Perez G; Ngo L; Marks PA
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation.
    Mahal K; Kahlen P; Biersack B; Schobert R
    Exp Cell Res; 2015 Aug; 336(2):263-75. PubMed ID: 26101158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
    Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
    Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
    Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
    J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
    Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
    Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer.
    Dhar S; Kumar A; Li K; Tzivion G; Levenson AS
    Biochim Biophys Acta; 2015 Feb; 1853(2):265-75. PubMed ID: 25447541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
    Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
    Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
    Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
    Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective HDAC6 inhibition prevents TNF-α-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema.
    Yu J; Ma Z; Shetty S; Ma M; Fu J
    Am J Physiol Lung Cell Mol Physiol; 2016 Jul; 311(1):L39-47. PubMed ID: 27190059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
    Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
    PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.